Single-Cell Genome Sequencing Market Report 2026

The single-cell genome sequencing market size has grown rapidly in recent years. It will grow from $2.83 billion in 2025 to $3.26 billion in 2026 at a compound annual growth rate (CAGR) of 15.2%. The growth in the historic period can be attributed to early adoption in research, limited sequencing resolution, high cost of single-cell analysis, growing demand for personalized medicine research, increasing collaborations in genomics.

The single-cell genome sequencing market size is expected to see rapid growth in the next few years. It will grow to $5.84 billion in 2030 at a compound annual growth rate (CAGR) of 15.7%. The growth in the forecast period can be attributed to development of high-throughput single-cell platforms, expansion in clinical diagnostic use, integration with AI and bioinformatics, adoption in multi-omics studies, growth in drug discovery applications. Major trends in the forecast period include increasing use in cancer research, integration with multi-omics studies, adoption in drug discovery, development of automated sequencing platforms, growth in clinical diagnostics applications.

The rising prevalence of cancer is expected to drive the growth of the single-cell genome sequencing market in the coming years. Cancer encompasses a group of diseases in which abnormal cells grow and divide uncontrollably, often due to genetic mutations that disrupt normal cell regulation and function. Single-cell genome sequencing plays a crucial role in identifying genetic changes occurring in individual cancer cells. For example, in January 2023, the American Cancer Society, a US-based cancer-focused organization, reported approximately 1.9 million new cancer cases and 609,360 cancer-related deaths in the US in 2022. Globally, it is estimated that by 2040, there will be around 27.5 million new cancer cases and 16.3 million cancer deaths. Therefore, the increasing incidence of cancer is expected to fuel the growth of the single-cell genome sequencing market.

Major companies in the single-cell genome sequencing market are emphasizing the development of single-cell proteomics, a field that studies protein expression at the level of individual cells. By integrating single-cell genomics with proteomics, researchers can analyze the relationship between genetic information and protein expression within single cells. For instance, in October 2023, Proteome Sciences plc, a UK-based biotechnology company, launched SysQuant SCP, a commercial single-cell proteomics service utilizing TMTpro™ isobaric labeling reagents. The SysQuant SCP pipeline generates and analyzes quantitative mass spectrometry data to detect subtle variations between individual cells and subpopulations of the same primary cell type. This approach provides novel diagnostic and therapeutic targets for personalized medicine, enhancing understanding of biological heterogeneity and disease evolution, as well as responses to therapy.

In January 2023, Qiagen, a Germany-based pharmaceutical research company, acquired Verogen for an undisclosed amount. The acquisition aims to strengthen Qiagen’s capabilities in human identification and forensic testing by incorporating Verogen’s next-generation sequencing (NGS) technology and expertise. Verogen is a US-based biotechnology company specializing in NGS-based solutions.

Major companies operating in the single-cell genome sequencing market are F Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., DH Life Sciences LLC., Becton Dickinson And Company (BD), Agilent Technologies Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN GmbH, Bio-Techne Corporation, BGI Genomics Co. Ltd., Fulgent Genetics Inc., 10x Genomics Inc., Promega Corporation, Takara Bio Inc., Oxford Nanopore Technologies PLC, Pacific Biosciences of California Inc., Standard BioTools Inc., Singleron Biotechnologies, MGI Tech Co. Ltd, GENEWIZ Inc., Mission Bio Inc., Zymo Research Corporation, Menarini Silicon Biosystems SpA, Novogene Co. Ltd., RareCyte Inc., Fluxion Biosciences Inc., Single Cell Discoveries B.V., Parse Biosciences Inc., BioSpyder Technologies Inc., SeqWell Inc.

North America was the largest region in the single-cell genome sequencing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the single-cell genome sequencing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the single-cell genome sequencing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the single-cell genome sequencing market by increasing costs for imported sequencing platforms, microfluidic devices, reagents, and automation systems. Academic research laboratories and biotechnology companies in Asia-Pacific and Europe are especially affected due to heavy reliance on international technology suppliers. These cost increases can slow adoption in cancer, immunology, and neurobiology research. At the same time, tariffs are driving local production of reagents and sequencing tools, improving long-term accessibility in the single-cell genome sequencing market.

The single-cell genome sequencing market research report is one of a series of new reports that provides single-cell genome sequencing market statistics, including single-cell genome sequencing industry global market size, regional shares, competitors with a single-cell genome sequencing market share, detailed single-cell genome sequencing market segments, market trends and opportunities, and any further data you may need to thrive in the single-cell genome sequencing industry. This single-cell genome sequencing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Single-cell genome sequencing is a powerful technique for identifying genomic alterations such as copy number variations (CNVs) and point mutations, as well as for uncovering cell-to-cell heterogeneity in biological samples. It is used to study both normal and diseased physiological conditions.

The main types of single-cell genome sequencing include instruments and reagents. Instruments are specialized devices or equipment used to carry out the various steps of the sequencing process. The technologies employed include next-generation sequencing (NGS), polymerase chain reaction (PCR), quantitative PCR (qPCR), microarray, and multiple displacement amplification (MDA). These are applied in disease areas such as cancer, immunology, prenatal diagnostics, neurobiology, microbiology, and others. Applications include analysis of circulating cells, cell differentiation or reprogramming, genomic variation, subpopulation characterization, and more, and are used by academic research laboratories, biotechnology and biopharmaceutical companies, clinics, and other end-users.

The single-cell genome sequencing market consists of revenues earned by entities by providing single-cell analysis, genetic heterogeneity study, identification of genomes of individual cells, and microbiomes and cancer study. The market value includes the value of related goods sold by the service provider or included within the service offering. The single-cell genome sequencing market also includes sales of single cell kit, DNA sequencing instruments and single-cell sequencing kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.